TCA Cellular Therapy said that the funding will help the company to continue the development of adult stem cell therapies for critical limb ischemia, cardiac ischemia, myocardial infarction, amyotrophic lateral sclerosis (ALS or Lou Gherig’s Disease), and spinal cord injury.
TCA Cellular Therapy president and medical director Gabriel Lasala said that the grant would assist the company in expanding the research for the treatment of multiple diseases and conditions.
QTDP was part of the Patient Protection and Affordable Care Act of 2010 and provides a 50% tax credit or grant to biotech, pharmaceutical and other healthcare companies for qualified investments by eligible companies in taxable years beginning in 2009 and in 2010 in connection with qualifying projects.